Rise in Drug Development and Launches by the Market Players to Propel the Global Cardio-Protective Drug Market Growth

The global cardio-protective drug market is anticipated to grow at a considerable CAGR of 3.9% during the forecast period. The players continue to deliver technological innovations to advance cardio-protective drug treatment. The various launches in the market are driving the growth of the market over the forecast period. For instance, in August 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US Food and Drug Administration (FDA) approved an expanded peripheral artery disease (PAD) indication for the XARELTO vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. With this approval, XARELTO is the first and only therapy indicated to reduce the risks of major cardiovascular (CV) events in patients with coronary artery disease (CAD) and major thrombotic vascular events, such as myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology, in patients with PAD, including patients who have recently undergone LER due to symptomatic PAD.

Furthermore, in December 2021, Novartis announced that the US FDA has approved Leqvio (inclisiran), the first small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year, after an initial dose and one at three months.

In September 2020, The National Institutes of Health launched two of three adaptive Phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19.

In March 2020, the US FDA approved two new non-statin drugs that clinical trials indicated can help reduce high cholesterol. Nexletol and Nexlizet can be used with statins that have moderate or minimal side effects.

In April 2019, Medtronic plc announced the U.S. launch of the Solitaire X Revascularization Device—and its first use in patients for the treatment of acute ischemic stroke.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Treatment 
• By Type
• By Application 
• By Distribution Channel

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- including Bayer AG, Bristol-Myers Squibb Co., GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

oDeviation from the pre-COVID-19 forecast

oMost affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Cardio-Protective Drug Market Report Segment

By Treatment 

• Cholesterol-Lowering
• Revascularization
• Anti-Inflammatory
• Blood Thinners & Clot Busters

By Type

• Antiplatelets
• Ace Inhibitors & Arbs
• Beta-Blockers
• Polypills
• Statins & Others

By Application 

• Arrhythmia
• Coronary Artery Disease
•  Ischemic Heart Disease
• Cardiovascular Disease
• Hyperlipidemia
• Peripheral Heart Disease
• Hypertension

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy 

Global Cardio-Protective Drug Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa

To learn more about this report request a free sample copy @ https://www.omrglobal.com/industry-reports/cardioprotective-drug-market 

Browse the full report description of “Global Cardio-Protective Drug Market Size, Share & Trends Analysis Report by Treatment (Cholesterol-Lowering, Revascularization, Anti-Inflammatory, and Blood Thinners & Clot Busters), by Type (Antiplatelets, Ace Inhibitors & Arbs, Beta-Blockers, Polypills, and Statins & Others), by Application (Arrhythmia, Coronary Artery Disease, Ischemic Heart Disease, Cardiovascular Disease, Hyperlipidemia, Peripheral Heart Disease, and Hypertension), and by Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/cardioprotective-drug-market